Vanguard Group Inc. Sells 491,281 Shares of Certara, Inc. $CERT

Vanguard Group Inc. trimmed its position in Certara, Inc. (NASDAQ:CERT) by 4.0% in the fourth quarter, Holdings Channel reports. The fund owned 11,916,099 shares of the company’s stock after selling 491,281 shares during the quarter. Vanguard Group Inc. owned 0.07% of Certara worth $104,981,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Associated Banc Corp lifted its stake in shares of Certara by 9.7% in the 3rd quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after acquiring an additional 1,051 shares during the last quarter. Versant Capital Management Inc lifted its stake in shares of Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after acquiring an additional 1,153 shares during the last quarter. Osaic Holdings Inc. lifted its stake in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares during the last quarter. Corient Private Wealth LLC lifted its stake in shares of Certara by 11.7% in the 2nd quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock valued at $144,000 after acquiring an additional 1,295 shares during the last quarter. Finally, Treasurer of the State of North Carolina increased its holdings in Certara by 2.9% in the second quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company’s stock valued at $663,000 after purchasing an additional 1,597 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Stock Performance

Shares of Certara stock opened at $5.09 on Wednesday. The company has a current ratio of 1.88, a quick ratio of 2.05 and a debt-to-equity ratio of 0.28. The business has a 50-day moving average price of $6.17 and a two-hundred day moving average price of $7.96. Certara, Inc. has a 1-year low of $4.97 and a 1-year high of $13.88. The company has a market cap of $780.40 million, a P/E ratio of -50.90 and a beta of 1.53.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. During the same quarter in the previous year, the business posted $0.14 earnings per share. The business’s revenue was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, analysts anticipate that Certara, Inc. will post 0.29 EPS for the current year.

Key Certara News

Here are the key news stories impacting Certara this week:

• Positive Sentiment: Certara said its AI investments are expected to support long-term growth, which could improve the company’s competitive positioning over time. Certara says AI investments will drive long-term growth – but traders are focused on one warning
• Neutral Sentiment: Certara guided 2026 revenue to $395 million-$405 million after divesting its medical writing business, giving investors a clearer picture of the company’s post-divestiture growth profile. Certara expects $395M-$405M 2026 revenue following medical writing divestiture
• Negative Sentiment: Multiple analysts lowered price targets after the earnings update, including Morgan Stanley to $10, Stephens to $9, Craig Hallum to $8, Barclays to $6.50, and Baird to $6, reinforcing a more cautious near-term outlook for CERT. Certara (NASDAQ:CERT) Price Target Lowered to $10.00 at Morgan Stanley
• Negative Sentiment: The company missed Q1 earnings estimates, and market coverage noted that the weak full-year guidance overshadowed the revenue beat, contributing to the stock’s decline. Certara Shares Slide on Outlook Cut, 1Q Loss
• Negative Sentiment: A shareholder investigation notice from Johnson Fistel may add legal overhang and investor uncertainty around Certara’s management disclosures. Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Analyst Ratings Changes

CERT has been the subject of a number of recent research reports. Stephens decreased their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday. KeyCorp decreased their price objective on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, April 13th. Craig Hallum decreased their price objective on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a report on Tuesday. Wall Street Zen downgraded Certara from a “buy” rating to a “hold” rating in a report on Sunday, February 15th. Finally, TD Cowen restated a “buy” rating on shares of Certara in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Certara has a consensus rating of “Hold” and a consensus price target of $8.85.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.